Akebia Ther Cash Flow Conversion Efficiency
Akebia Ther cash flow conversion efficiency. Based on the latest financial reports, Akebia Ther (AKBA) has a cash flow conversion efficiency ratio of 0.955x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($31.13 Million) by net assets ($32.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Akebia Ther (2012–2025)
Cash flow conversion efficiency of Akebia Ther from 2012 to 2025. This chart illustrates how Akebia Ther's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AKBA stock price for real-time trading data and today's change.
Akebia Ther Cash Flow Conversion Ratio Explained
Akebia Ther cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Akebia Ther Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akebia Ther ranked by their cash flow conversion efficiency. Also see Akebia Ther market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Digital Currency X Technology Inc.
NASDAQ:DCX
|
-0.005x |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089
|
0.034x |
|
Yuan Jen Enterprises Co Ltd
TW:1725
|
-0.002x |
|
CHEMTRONICS.CO.Ltd
KQ:089010
|
0.009x |
|
Lynch Group Holdings Ltd
AU:LGL
|
0.146x |
|
Ares Commercial Real Estate
NYSE:ACRE
|
0.014x |
|
Gyldendal A/S
CO:GYLD-A
|
-0.048x |
|
Studio City International Holdings Ltd
NYSE:MSC
|
0.015x |
Annual Cash Flow Conversion Efficiency for Akebia Ther (2012–2025)
The table below shows the annual cash flow conversion efficiency of Akebia Ther from 2012 to 2025. Review cash generation quality of Akebia Ther to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $32.61 Million | $67.99 Million | 2.085x | +152.22% |
| 2024-12-31 | $-49.19 Million | $-40.66 Million | 0.827x | +8.12% |
| 2023-12-31 | $-30.58 Million | $-23.38 Million | 0.765x | +105.47% |
| 2022-12-31 | $5.23 Million | $-73.15 Million | -13.987x | -309.22% |
| 2021-12-31 | $74.01 Million | $-252.97 Million | -3.418x | -666.73% |
| 2020-12-31 | $247.62 Million | $-110.39 Million | -0.446x | +31.64% |
| 2019-12-31 | $394.76 Million | $-257.44 Million | -0.652x | -325.38% |
| 2018-12-31 | $635.93 Million | $-97.49 Million | -0.153x | +67.42% |
| 2017-12-31 | $119.33 Million | $-56.16 Million | -0.471x | -155.36% |
| 2016-12-31 | $68.12 Million | $57.91 Million | 0.850x | +312.48% |
| 2015-12-31 | $131.00 Million | $-52.41 Million | -0.400x | -51.50% |
| 2014-12-31 | $104.08 Million | $-27.48 Million | -0.264x | +28.33% |
| 2013-12-31 | $30.76 Million | $-11.33 Million | -0.368x | -113.69% |
| 2012-12-31 | $-2.68 Million | $-7.21 Million | 2.691x | -- |
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and … Read more